Rising Incidence Of Bone Marrow Cancer Fuels Growth Of Daratumumab/Darzalex Market: A Key Factor Shaping the Future of the Daratumumab Or Darzalex Market in 2025

What combination of drivers is leading to accelerated growth in the daratumumab or darzalex market?
The escalation of bone marrow cancer occurrences is anticipated to stimulate the expansion of the daratumumab or darzalex market. Bone marrow cancer entails cancers initiating in the bone marrow like multiple myeloma and leukemia which disrupt normal bodily functions due to abnormal blood cell production. The surge in bone marrow cancers is linked to an ageing population, improved detection techniques, and additional influences such as environmental factors, lifestyle decisions, and genetic susceptibility. Daratumumab or Darzalex works against multiple myeloma, a kind of bone marrow cancer, by identifying and eliminating abnormal plasma cells in the bone marrow. As per the data shared by the American Cancer Society in January 2024, a non-profit US organization dedicated to cancer eradication, the projections showed 89,190 lymphoma cases against 89,010 in 2022 and 35,780 myeloma cases against 34,470 in 2022. Thus, the escalating occurrences of bone marrow cancer are propelling the daratumumab or darzalex market's expansion. The growing acceptance of targeted therapies and biologics is set to accelerate the daratumumab or darzalex market's growth in future. Targeted therapies are medical treatments that utilize drugs or other substances to accurately locate and attack specific molecules that assist cancer or other diseases grow and survive. The use of biologics and targeted therapies is on the rise due to the increasing incidence of chronic diseases and advancements in precision medicine, which aid in designing more effective, personalized treatments. Due to its specific action on CD38, a protein highly expressed on the surface of malignant plasma cells in multiple myeloma, daratumumab is used in targeted therapies. As stated by the Advanced Therapy Treatment Centers (ATTC) in December 2023, an UK-based network that aims to introduce new advanced therapy medicinal products (ATMPs) to patients, annual investments in advanced therapies saw a rise by 31% in 2022, with the UK contributing to 14% of all global commercial ATMP clinical trials. Consequently, the growing acceptance of biologics and targeted therapies is propelling the daratumumab or darzalex market's growth.

Get Your Daratumumab Or Darzalex Market Report Here:
https://www.thebusinessresearchcompany.com/report/daratumumab-or-darzalex-global-market-report

What is the projected compound annual growth rate (CAGR) of the daratumumab or darzalex market from 2025 to 2034, and what factors influence it?
The market for daratumumab, also known as darzalex, has witnessed rapid expansion over the past few years. The market is expected to surge from $5,093.04 million in 2024 to $5,618.30 million in 2025, marking a compound annual growth rate (CAGR) of 10.3%. The significant growth during the historical period can be linked to factors such as the employment of diverse research channels, the enhanced viability of biomanufacturing processes, the increased application of monoclonal antibodies, the rise in strategic initiatives, and the augmented production of mAbs.

Anticipated surges in the daratumumab or darzalex market size are on the horizon, expecting to reach a worth of $8,189.36 million by 2029, boasting a compound annual growth rate (CAGR) of 10.0%. Various factors contribute to this projected growth in the forecast period, like the rising number of clinical evidence proving its efficacy, its increased use in initial treatment procedures, heightened demand for biological products, improving patient knowledge levels, increased occurrences of blood cancer, and the growing presentment of chronic diseases. The period's key trends include technological progression, the launching of new products, the provision of products and/or services, forming of partnerships, mergers and acquisitions taking place, advancements in radiation application methodologies, and strategic collaborations.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19896&type=smp

How are the latest trends influencing the growth of the daratumumab or darzalex market?
The primary trend in the daratumumab or darzalex market is a focus on switching from traditional cancer treatments to early intervention strategies such as combination therapies for better effectiveness in the treatment of multiple myeloma and other types of cancers. Combination therapies are treatment plans that employ two or more therapeutic drugs with diverse action mechanisms, often synergistically, to enhance treatment effectiveness, reduce resistance, and potentially minimize harmful side effects compared to single-drug therapy. For example, Johnson & Johnson, a pharmaceutical company based in the United States, got approval from the U.S. FDA in July 2024 for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) to be used in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for starting and consolidation therapy in patients newly diagnosed with multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT). This approval solves a pressing need for a quadruplet therapy option at the time of initial diagnosis, which could potentially enhance patient outcomes.

What are the major segments of the daratumumab or darzalex market and their role in driving growth?
The daratumumab or darzalexmarket covered in this report is segmented -

1) By Drug Type: 100Mg Injection; 400Mg Injection
2) By Distribution Channel: Pharmacies; Hospital; Other Distribution Channels
3) By Application: Follicular Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma; Diffuse Large B Cell Lymphoma; Other Applications

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/Discount?id=19896&type=discount

Which regions are key players in the growth of the daratumumab or darzalex market?
North America was the largest region in the daratumumab or darzalex market in 2024. The regions covered in the daratumumab or darzalex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the daratumumab or darzalex market?
Major companies operating in the daratumumab or darzalex market include Genmab A/S, Janssen Biotech Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=19896&type=smp

What Is Covered In The Daratumumab Or Darzalex Global Market Report?

•Market Size Forecast: Examine the daratumumab or darzalex market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the daratumumab or darzalex market for a structured understanding.
•Key Players Overview: Analyze major players in the daratumumab or darzalex market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the daratumumab or darzalex market.
•Segment Contributions: Evaluate how different segments drive overall growth in the daratumumab or darzalex market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the daratumumab or darzalex market.
•Industry Challenges: Identify potential risks and obstacles affecting the daratumumab or darzalex market.
•Competitive Landscape: Review strategic developments in the daratumumab or darzalex market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.